The DOI matches its Crossref record; 452 of the 452 references it cites were found in a registry or an index; 480 of the 632 sources its claims cite were checked for support.
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Open accessAbstract
Major depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief. Rapid-acting antidepressants reshaped the field by linking swift symptom improvement to glutamatergic plasticity, yet durable benefit depends on how newly reconfigured circuits are stabilized and tuned. This review synthesizes evidence that antidepressant efficacy arises from the coordinated engagement of synaptic plasticity, spanning induction and consolidation, and intrinsic excitability, which provides gain control, and proposes an integrated framework to guide future discovery. It first outlines induction through N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), exemplified by ketamine and esketamine, followed by consolidation mediated by tropomyosin receptor kinase B (TrkB) signaling, translational disinhibition via eukaryotic elongation factor 2 kinase (eEF2K), and presynaptic stabilization indexed by synaptic vesicle glycoprotein 2A (SV2A); together, these processes transform transient potentiation into persistent network change. It then highlights intrinsic excitability, emphasizing voltage-gated potassium channel subfamily Q (Kv7), hyperpolarization-activated cyclic nucleotide-gated (HCN), and G protein-gated inwardly rectifying potassium (GIRK) channels as circuit-level governors that normalize firing and limit relapse-prone hyperexcitability. Finally, it presents the Induction–Consolidation–Maintenance (ICM) framework as a hypothesis-generating roadmap for future studies, with SV2A positron emission tomography (PET), electroencephalography (EEG), and functional magnetic resonance imaging (fMRI) biomarkers discussed as candidate tools rather than validated guides for treatment timing or patient selection. The proposed contribution is not another list of plasticity pathways, but a phase-specific model that links synaptic induction, consolidation, and excitability-based maintenance to distinct therapeutic windows, biomarkers, and relapse-prevention strategies.
Overview
CoChat Summary
TL;DR
This narrative review proposes the Induction–Consolidation–Maintenance (ICM) framework, which treats antidepressant response as a temporally ordered process in which glutamatergic synaptic plasticity is induced, consolidated, and then stabilized by intrinsic excitability tuning. It argues that durable remission requires pairing plasticity inducers (e.g., ketamine/esketamine) with consolidation and maintenance mechanisms (TrkB, eEF2K, SV2A) and ion-channel–based gain control (Kv7, HCN, GIRK).
Key findings
- Antidepressant action is reframed as three mechanistically distinct phases: induction via NMDAR/AMPAR glutamatergic signaling (ketamine, esketamine, DXM-bupropion), consolidation via TrkB signaling, eEF2K-mediated translational disinhibition, and presynaptic stabilization indexed by SV2A, and maintenance via intrinsic excitability.
- Rapid glutamatergic strategies reliably produce rapid relief but responses "frequently decay within days to weeks, with high relapse rates following discontinuation"; maintenance regimens only partially offset this erosion.
- Intrinsic excitability channels are positioned as the maintenance layer: Kv7 (M-current) openers dampen hyperexcitability and show the strongest clinical signal (ezogabine reduced depressive symptoms and improved reward sensitivity in MDD with anhedonia, but pigmentation/urinary liabilities limited use), whereas HCN and GIRK strategies remain "largely mechanistic or preclinical."
- Translational failures are treated as boundary conditions: rapastinel failed to meet primary endpoints in three pivotal phase 3 adjunctive MDD trials, and no clinical-grade eEF2K inhibitor exists; TrkB agonists face reproducibility and target-specificity concerns.
Methods
- Narrative review synthesizing heterogeneous preclinical and clinical evidence; the author states the ICM framework "is used to organize heterogeneous evidence rather than to rank mechanisms by clinical readiness."
- Ketamine is treated as the best-established clinical entry point into rapid plasticity, with non-ketamine pathways discussed "according to their current evidentiary maturity."
- No systematic search strategy, inclusion criteria, or quantitative synthesis is reported; the paper is organized into sections on induction/consolidation, presynaptic and network integrity (SV2A), intrinsic excitability (Kv7, HCN, GIRK), combinatorial strategies, and future directions.
Limitations
- Stated: the ICM framework is "a narrative synthesis rather than a validated clinical algorithm"; biomarkers (SV2A PET, MRS, EEG, fMRI, actigraphy) "are not yet validated tools for routine patient stratification"; and TrkB modulators, eEF2K inhibitors, SV2A enhancers, and ion-channel strategies remain at earlier stages of translation than ketamine/esketamine.
- Stated: long-term modulation of plasticity pathways may stabilize maladaptive circuits, alter excitation–inhibition balance, or change seizure thresholds; concerns include off-target signaling, abuse liability, and uncertainty about chronic ketamine/esketamine exposure.
- Evident from the text: the review is single-authored and non-systematic, with no stated search protocol or evidence-grading method, so the relative weighting of mechanisms reflects the author's narrative judgment; the author also notes that figures and tables "should be read as organizing tools... not as evidence that all pathways or targets are equally validated."
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
189 Valid · 51 Not valid · 24 Not checked · 56 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Through these convergent actions, SV2A functions as a molecular scaffold that stabilizes presynaptic terminals while postsynaptic strengthening consolidates [175,184,198].”
§ Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery > 3. Stabilizing Presynaptic and Network Integrity > Synaptic Vesicle Glycoprotein 2A (SV2A) Enhancers
What the sources say
- Disputedcites [175] Gillard, 2016, Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond, CNS Drugs sourceExperimental — accuracy not yet measured
In “Excitability in the Brain” (page not provided), the paper says SV2 proteins are not structural components of synapses and instead links SV2A to control of vesicle exocytosis. That contradicts the attributed role of SV2A as a scaffold stabilizing presynaptic terminals; the passage does not describe coordinated postsynaptic strengthening. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [184] Stout, 2019, The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance, ACS Chem. Neurosci. source
- Partly supportedcites [198] Nowack, 2010, SV2 regulates neurotransmitter release via multiple mechanisms, Am. J. Physiol. Cell Physiol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that SV2 contributes to presynaptic release probability and describes a vesicular-matrix scaffold as a hypothesis tested in the study. It does not establish that SV2A stabilizes presynaptic terminals or link its action to the consolidation of postsynaptic strengthening. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Rather than increasing synapse number or global firing, it selectively scales AMPAR mediated currents, producing a controlled gain in synaptic efficacy [147,152,154,155].”
§ Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery > 2. Induction and Consolidation of Synaptic Plasticity > 2.3. eEF2K Inhibitors
What the sources say
- Not checked — no full text of the sourcecites [147] Suzuki, 2020, The role of eEF2 kinase in the rapid antidepressant actions of ketamine, Adv. Pharmacol. source
- Disputedcites [152] Weng, W., Chen, Y., Wang, M., Zhuang, Y., and Behnisch, T. (2016). Potentiation of Schaffer-Collateral CA1 Synaptic Transmission by eEF2K and p38 MAPK Mediated Mechanisms. Front. Cell. Neurosci., 10. sourceExperimental — accuracy not yet measured
The Discussion reports that eEF2K inhibition enhances synaptic transmission by increasing presynaptic vesicle-release probability, without changing the amplitude of synaptic events. It explicitly contrasts this with a change in glutamate-receptor density or conductance, which would have changed EPSC amplitude. The paper therefore supports a gain in synaptic transmission, but not the claimed selective scaling of AMPAR-mediated currents. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [154] Beretta, 2022, Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K), Mol. Autism sourceExperimental — accuracy not yet measured
The Results section ('eEF2K deletion enhances GABAergic transmission'; page unavailable) says excitatory postsynaptic currents were unchanged in previously studied eEF2K-deficient mice, while inhibitory currents increased. In the Dravet mouse model, the authors measured enhanced inhibitory currents and conclude in the Discussion (page unavailable) that eEF2K deletion selectively increases GABAergic transmission—not AMPAR-mediated currents. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [155] Wierenga, 2005, Postsynaptic expression of homeostatic plasticity at neocortical synapses, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion reports that activity blockade in young neocortical cultures increased postsynaptic AMPAR accumulation and synaptic strength without significantly increasing excitatory synapse number. It does not attribute these effects to eEF2K inhibition, and it says increased boosting by sodium channels also contributed to the stronger currents, so the claim of selective AMPAR-current scaling is not fully supported. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In prefrontal and hippocampal circuits, channels such as voltage-gated potassium channel subfamily Q (Kv7), hyperpolarization-activated cyclic nucleotide-gated channel (HCN), and G protein-gated inwardly rectifying potassium gated channel (GIRK; Kir3.x) serve as key determinants of firing probability and network stability [27,28,29].”
§ Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery > 1. Introduction: Beyond Monoamines to Plasticity and Excitability
What the sources say
- Partly supportedcites [27] Klemz, A., Wildner, F., Tütüncü, E., and Gerevich, Z. (2021). Regulation of Hippocampal Gamma Oscillations by Modulation of Intrinsic Neuronal Excitability. Front. Neural Circuits, 15. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says Kv7.2/3 channels regulate neuronal excitability and that blocking them increases gamma-oscillation power in hippocampal CA3 circuits. The Introduction (page unavailable) says HCN channels were excluded from the study. The cited paper does not establish the sentence’s broader claim about Kv7, HCN, and GIRK channels across both prefrontal and hippocampal circuits. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [28] Desai, 1999, Plasticity in the intrinsic excitability of cortical pyramidal neurons, Nat. Neurosci. source
- Not checked — no full text of the sourcecites [29] Brandalise, 2020, Conditioning by subthreshold synaptic input changes the intrinsic firing pattern of CA3 hippocampal neurons, J. Neurophysiol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Chronic stress induces cell-type-specific shifts in intrinsic excitability within medial prefrontal and hippocampal neurons, biasing circuits toward vulnerability or resilience depending on channel composition and neuromodulatory state [25,26].”
§ Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery > 1. Introduction: Beyond Monoamines to Plasticity and Excitability
What the sources say
- Partly supportedcites [25] Debanne, 2019, The contribution of ion channels in input-output plasticity, Neurobiol. Learn. Mem. sourceExperimental — accuracy not yet measured
The sections on homeostatic plasticity and GABAergic interneurons describe cell-type-dependent changes in intrinsic excitability involving ion channels, including in hippocampal neurons. They discuss activity deprivation and synaptic stimulation, not chronic stress; the passages do not establish shifts in medial prefrontal neurons or a resulting bias toward vulnerability or resilience. (LLM, conf=0.84)
- Could not verifycites [26] Hansel, C., and Yuste, R. (2024). Neural ensembles: Role of intrinsic excitability and its plasticity. Front. Cell. Neurosci., 18. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses hippocampal excitability after conditioning, and the section on on/off modulation discusses SK channels and cholinergic signaling. Neither addresses chronic stress, medial prefrontal excitability, or vulnerability versus resilience. Searches for those terms found no passage supporting the attributed claim. (LLM, conf=0.74)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For early plasticity to last, downstream signaling must stabilize structure, transcription, and protein synthesis [34,41].”
§ Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery > 2. Induction and Consolidation of Synaptic Plasticity
What the sources say
- Partly supportedcites [34] Kennedy, 2013, Synaptic Signaling in Learning and Memory, Cold Spring Harb. Perspect. Biol. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) describes early structural changes followed by signaling that increases local protein synthesis and activates transcription; it says these later changes can affect neuronal structure for hours to a lifetime. It does not establish that all three processes must be stabilized for early plasticity to last, so the claim overstates their necessity. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [41] Shrestha, 2022, Spatiotemporally resolved protein synthesis as a molecular framework for memory consolidation, Trends Neurosci. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
89 more claims · 66 with their cited sources checked
Create a free account to see all 320 claims and to verify the 4 references still open.
- It may state two separate claims as one. 211
- Probably not a substantial claim. 41
- The quote only partly states this claim. 1
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Liebetanz, D. (2002) · Brain · doi:10.1093/brain/awf238 · Cited by 1,383
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis
Bramham, C. R., & Messaoudi, E. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.003 · Cited by 1,193
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Metadata
- Authors
- Tanaka, M.
- Affiliations
- University of Szeged (HU)
- Corresponding author
- Tanaka, Masaru
- ORCID
- Tanaka, Masaru
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2026-06-01
- Volume
- 14
- Issue
- 6
- Pages
- 1265
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC13296422
- OpenAlex
- W7163031031
- Cited by
- 0
- References
- 431
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- synaptic plasticity, intrinsic excitability, major depressive disorder, rapid-acting antidepressants, NMDA receptor, AMPA receptors, ketamine, esketamine, TrkB signaling, eEF2K, SV2A, Kv7 channels, HCN channels, GIRK channels, gain control, hyperexcitability, relapse prevention, PET biomarkers, EEG biomarkers, fMRI biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery. https://app.cochat.ai/papers/10.3390/biomedicines14061265
- The paper
- Tanaka, M. (2026). Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery. Biomedicines. https://doi.org/10.3390/biomedicines14061265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.